 The aim of this study is to determine if virologically suppressed human immunodeficiency virus type 1 HIV-1 infected adults on an antiretroviral regimen including 2 nucleoside reverse transcriptase inhibitors NRTIs plus a third agent remain suppressed upon switching to a two-drug regimen with dolutegravir DTG rilpivirine RPV. The study will primarily assess the non-inferiority antiviral activity of switching to DTG RPV once daily compared to continuation of current antiretroviral regimen CAR up to Week 48 with a switch visit for eligible subjects in the CAR group to initiate DTG RPV therapy at Week 52. CAR will include 2 NRTIs plus 1 HIV-1 integrase inhibitor INI, or 1 non-nucleoside reverse transcriptase inhibitor NNRTI, or 1 protease inhibitor PI. The study will include a 148-week open-label treatment phase, comprising of an Early Switch Phase Day 1 to Week 52 and a Late Switch Phase Week 52 to Week 148. The participants fulfilling the study eligibility criteria will participate in the Early Switch Phase where they will either switch from their CAR to DTG RPV, or continue taking their CAR, until Week 52. At the end of Early Switch Phase, eligible participants will proceed to the Late Switch Phase where all participants in both DTG RPV and CAR treatment groups will receive DTG RPV therapy until Week 148. After Week 148, subjects may be eligible to continue to receive DTG RPV in the Continuation Phase. The study is planned to be conducted in approximately 476 participants. 